Table 1

Baseline patient characteristics

nwtATTR-CM (N=432)
Age at diagnosis (years)43277 (73–82)
Male gender432409 (95)
Caucasian ancestry432402 (93)
NAC ATTR stage I432210 (49)
NAC ATTR stage II432161 (37)
NAC ATTR stage III43261 (14)
NT-proBNP (ng/L)4322760 (1568–4904)
eGFR (MDRD, mL/min)43260 (49–74)
 CKD stage ≤I24 (6)
 CKD stage II196 (45)
 CKD stage IIIa130 (30)
 CKD stage IIIb66 (15)
 CKD stage IV16 (4)
 CKD stage V0 (0)
Troponin T (ng/L)38958 (40–81)
Serum albumin (g/L)43244 (42–46)
NYHA heart failure class432
 I53 (12)
 II298 (69)
 III77 (18)
 IV4 (1)
Comorbidities432
 Hypertension147 (34)
 Atrial fibrillation226 (52)
 Diabetes mellitus54 (13)
 Pacemaker66 (15)
Systolic blood pressure (mm Hg)432122 (111–135)
Diastolic blood pressure (mm Hg)43272 (67–79)
Body mass index (kg/m2)43226 (24–29)
IVSd (mm)42717 (16–18)
LVPWd (mm)42716 (15–18)
Left ventricular ejection fraction (%)42348 (42–56)
6MWT (m)313358 (230–449)
Perugini grade on DPD scan380
 Grade 2349 (92)
 Grade 331 (8)
  • Results displayed as number (percentage) for categorical variables and median (IQR) for numerical variables.

  • CKD, chronic kidney disease; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; eGFR, estimated glomerular filtration rate; IVSd, interventricular septal thickness at end diastole; LVPWd, left ventricular posterior wall thickness at end diastole; MDRD, Modification of Diet in Renal Disease; 6MWT, 6 min walk test; NAC ATTR stage, National Amyloidosis Centre transthyretin amyloidosis stage; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; wtATTR-CM, wild-type transthyretin amyloid cardiomyopathy.